ConfusionWhat was lost in this Arbitration Judgement ?
It would be nice to get some better detail of the Arbitration proceeding and ruling. The shareholders never really received any information regarding what Replicel's case was against Shiseido and vica versa
Here is really all we were told as the Arbitration claim was submitted Oct. 18th 2021 by Replicel from Acceswire:
"After several unsuccessful attempts to settle the dispute, RepliCel has filed an arbitration claim seeking Shiseido's full compliance with the agreement or return of the license and all collaboration data and innovations related to its cell therapy treatment for male and female pattern hair loss."
According to Andrew's N/R Oct. 16th:
"The tribunal dismissed RepliCel's claims finding that Shiseido validly terminated the collaboration and technology transfer agreement dated effective as of July 9, 2013".
What does this all mean? Obviously Shiseido can pursue this hair treatment technology without restriction or impedement in Asia and does not have to transfer any Trial data to Replicel.
The question for me here is does this give Shiseido exclusive rights in Asia or can Replicel also pursue it's own marketing of RCH-01 in Asia? I would assume they can.
This screams out for an update from Andrew and Jamie as to what is the plan moving forwar in this regard.